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Background. Epstein-Barr virus (EBV) is the major environmental factor associated with Hodgkin’s lymphoma (HL), a common
lymphoma in young adults. Natural killer (NK) cells are key actors of the innate immune response against viruses. The
regulation of NK cell function involves activating and inhibitory Killer cell Immunoglobulin-like receptors (KIRs), which are
expressed in variable numbers on NK cells. Various viral and virus-related malignant disorders have been associated with the
presence/absence of certain KIR genes in case/control studies. We investigated the role of the KIR cluster in HL in a family-
based association study. Methodology. We included 90 families with 90 HL index cases (age 16–35 years) and 255 first-degree
relatives (parents and siblings). We developed a procedure for reconstructing full genotypic information (number of gene
copies) at each KIR locus from the standard KIR gene content. Out of the 90 collected families, 84 were informative and suitable
for further analysis. An association study was then carried out with specific family-based analysis methods on these 84 families.
Principal Findings. Five KIR genes in strong linkage disequilibrium were found significantly associated with HL. Refined
haplotype analysis showed that the association was supported by a dominant protective effect of KIR3DS1 and/or KIR2DS1,
both of which are activating receptors. The odds ratios for developing HL in subjects with at least one copy of KIR3DS1 or
KIR2DS1 with respect to subjects with neither of these genes were 0.44[95% confidence interval 0.23–0.85] and 0.42[0.21–
0.85], respectively. No significant association was found in a tentative replication case/control study of 68 HL cases (age 18–
71 years). In the familial study, the protective effect of KIR3DS1/KIR2DS1 tended to be stronger in HL patients with detectable
EBV in blood or tumour cells. Conclusions. This work defines a template for family-based association studies based on full
genotypic information for the KIR cluster, and provides the first evidence that activating KIRs can have a protective role in HL.
Citation: Besson C, Roetynck S, Williams F, Orsi L, Amiel C, et al (2007) Association of Killer Cell Immunoglobulin-Like Receptor Genes with Hodgkin’s
Lymphoma in a Familial Study. PLoS ONE 2(5): e406. doi:10.1371/journal.pone.0000406
INTRODUCTION
Hodgkin’s lymphoma (HL) differs from other lymphomas in terms
of both specific pathological and epidemiological features. HL is
characterised by the presence of large tumour cells known as
Hodgkin and Reed-Sternberg cells, derived from a germinal centre
B cell [1]. The incidence of HL displays an unusual age distri-
bution, with two peaks—between the ages of 15 to 34 years and
over the age of 60 years in most Western countries, but in children
and in the oldest age groups in developing countries [2]. HL is one
of the most common forms of lymphoma occurring in young
adults in developed countries, with an annual incidence of around
3 per 100,000 [2,3]. Both genetic and environmental factors are
thought to be involved in the pathogenesis of HL [2]. There is
growing evidence to suggest a genetic predisposition to HL, based
on many reports of familial aggregation of the disease [4–6],
including a twin study [7]. Interestingly, a review of these studies
found that familial HL lacked the classic bimodal age distribution,
with only one peak observed, between the ages of 15 and 34 years
[6]. Several variants of the major histocompatibility complex
(MHC) region have been reported to be associated with HL [8–
10], but there is no consensus on the role of specific human
leukocyte antigen (HLA) alleles or haplotypes in HL. In the only
genome-wide scan by linkage analysis conducted to date,
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suggestive evidence was obtained for a HL susceptibility locus on
chromosome 4p16 [11]. The genetic basis of HL thus remains
elusive.
Several findings strongly suggest that Epstein-Barr virus (EBV) is
a major environmental factor contributing to oncogenesis in HL
[12,13]. EBV clonal DNA is identified in the Reed-Sternberg cells
in around 30% of cases of HL, and EBV infection is thought to
provide survival signals for these abnormal B cells, leading to their
proliferation [14]. Moreover, epidemiological studies have clearly
shown that the risk of developing HL be up to three times higher
in subjects with a previous history of infectious mononucleosis—the
symptomatic form of primary EBV infection, particularly frequent in
adolescence—than in other subjects [15]. HL patients have also been
found to have high EBV antibody titres at the time of HL diagnosis,
and years before and after diagnosis [16]. All these findings suggest
that impairment of the immune response to EBV infection may
contribute to the pathogenesis of HL. Natural killer (NK) cells are
key actors of the innate immune response to viruses [17] [18],
including EBV [19,20]. Their role is illustrated by the recent report
of a child who developed an EBV-driven lymphoproliferative
disorder associated with a novel specific NK cell deficiency [21].
Further support for an involvement of these cells in innate immunity
to viruses has been provided by experimental models as susceptibility
to murine cytomegalovirus (MCMV), another herpes-virus, is
controlled by a single gene, Ly49H (also called Klra8) encoding an
NK activating receptor in mice [22,23].
The human Killer cell Immunoglobulin-like receptor (KIR) genes
correspond functionally to the murine Ly49 gene family, providing
a potential example of convergent evolution [24]. KIRs are
inhibitory or activating transmembrane receptors, present on the
surface of NK cells [25]. The length of their intracytoplasmic
domains—long (KIR-L), or short (KIR-S)—determines whether
they are inhibitory (KIR-L) or activating (KIR-S). Inhibitory KIRs
are essential for the regulation of NK cell function via interactions
with MHC class I molecules [26]. The ligands of activating KIRs
are less well known, although recent results have suggested that
activating and inhibitory receptors recognise the same sets of
peptide-MHC class I complexes, but differ in binding affinities
[27]. The common Human Genome Organization (HUGO)
nomenclature for KIRs will be used throughout this report
(Figure 1). The HUGO nomenclature accounts for KIR protein
structure and consists of four major subdivisions based on two
features: the number of extracellular Ig domains (2D or 3D) and
the length of the cytoplasmic tail (L or S). The KIRs are encoded
by a cluster of genes (Figure 1) varying considerably between
individuals, resulting in the expression of between seven and 12
receptors [26]. KIR gene polymorphism adds further variability,
with multiple alleles identified for each KIR locus, but the principal
source of diversity in the KIR region remains the presence/absence
of KIR genes. Several case/control studies have reported an
association between the presence/absence of specific KIRs and
disease progression following infection with some oncogenic
viruses [25]. For example, the presence of activating KIR3DS1 in
combination with its HLA class I ligand (the Bw4I80 allele) has
been shown to protect against progression to acquired immuno-
deficiency syndrome in HIV-infected patients [28], and against the
development of hepatocellular carcinoma in hepatitis C virus-
infected patients [29]. However, the presence of this gene has also
been associated with an increase in the risk of human papilloma
virus-induced cervical cancer [30]. Consistent with this finding,
patients with EBV-associated nasopharyngeal carcinoma (NPC)
tend to have more activating KIRs than controls [31].
Alltogether these data suggest that KIRs may be involved in the
pathogenesis of virus-induced malignancies, although the role of
activating and inhibitory receptors remains unclear. In the present
work, we investigate the role of KIRs in the occurrence of HL.
Our main study was based on a familial design, presenting two major
advantages. First, we were able to use full genotypic information for
KIR loci (number of gene copies), with the corresponding haplotypes,
rather than the phenotypic information (presence/absence of the
gene) used in previously published case/control designs investigating
the association of KIRs with other virus-induced diseases. Second,
family-based association studies are not subject to the possible
confounding of gene-phenotype associations due to inappropriately
chosen controls or population substructures. Our results for this
familial sample show that some activating KIRs have a protective
effect against HL, although this association was not reproduced in
a tentative replication case/control study.
RESULTS
KIR gene content in HL patients
Our sample consisted of 90 nuclear families, including 345 subjects
(90 index HL cases, 2 affected parents, 143 unaffected parents, 3
affected sibs and 107 unaffected sibs). The mean age at diagnosis
of the 90 index cases of HL was 26.2 years (range 16 to 35 years).
The index cases comprised 51 men (57%) and 39 women (43%).
The main morphological group was nodular sclerosis (87%),
followed by mixed cellularity (10%). Figure 2 shows the distribu-
tion of the presence of the variable KIRs, as determined by KIR
gene content analysis for the HL index cases (n = 90). The pro-
portion of HL cases with a positive KIR phenotype varied from
23% for KIR2DS3 to more than 95% for KIR2DL1. Standard KIR
gene content analysis provides only binary phenotypic results for
each KIR (absent or present), with no information about the
number of copies/alleles (1 or 2) when the KIR is present. As our
analysis focuses on the genotypes (number of copies) of each of the
nine variable KIR genes shown in figure 1 (KIR2DS2, KIR2DL2/
2DL3, KIR2DL1, KIR3DS1/3DL1, KIR2DL5, KIR2DS3, KIR2DS5,
KIR2DS1, KIR2DS4), we first reconstructed the genotypes from the
KIR gene content results.
Genotype reconstruction in families
The procedure used for genotypic reconstruction is described in
detail in Figure 3. In the first step, genotypes could be unambi-
guously determined for all negative KIR phenotypes, and for the
two KIR genes with known allelic forms, KIR2DL2/2DL3 and
KIR3DS1/3DL1. Allele typing for KIR2DS4 distinguished between
the two forms—KIR2DS4wt and KIR2DS4del—making it possible
to reconstruct most of the genotypes for this receptor. Finally, an
analysis of familial segregation provided additional genotype
determination, resulting in 60% to 100% of the genotypes being
known (Table 1), for all KIRs except KIR2DL1. The very small
number of negative subjects (10/345) and the absence of addi-
tional information for KIR2DL1 made it impossible to distinguish
between heterozygous KIR2DL1 (+,2) and homozygous KIR2DL1
(+,+) in most families. Based on both genotypic reconstitution and
additional allele typing of the anchor gene KIR2DL4, two families
with Mendelian inconsistencies were excluded. Four additional
families were also excluded, as individuals did not fit the pattern of
familial segregation at two adjacent loci, KIR2DL4 and KIR3DS1/
3DL1, due either to Mendelian incompatibilities or to possible
deletion of these loci in one haplotype. Finally, the sample
subsequently used for linkage disequilibrium (LD) and association
studies consisted of 84 families, comprising 322 subjects and
including a total of 88 HL patients.
We then estimated pairwise LD between KIRs based on the
genotypes determined in this first reconstruction step (Figure 4). As
KIRs and Hodgkin’s Lymphoma
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previously reported, the KIR region was in strong LD, and two pairs
of KIRs were found to be in perfect LD (r2 = 1). KIR2DS1 and
KIR2DS4 were in perfect negative LD—the presence of one gene in
a given haplotype excluding the presence of the other, with only two
haplotypes, KIR2DS1+/KIR2DS4- and KIR2DS1-/KIR2DS4+, ob-
served. KIR2DL2 and KIR2DS2 were in perfect positive LD—with
only the KIR2DL2+/KIRDS2+ and KIR2DL2-/KIRDS2- haplotypes
observed. These findings, which are fully consistent with previously
reported haplotypes [26], made possible the complete genotypic
determination of these four KIRs. Three of the four remaining KIRs
that were not fully reconstructed, KIR2DL5, KIR2DS3 and KIR2DS5,
presented complete LD (|D’| = 1) with several other KIRs (Figure 4).
Based on these observations, genotypes at these three KIRs could be
determined for most subjects. Reconstruction of the few remaining
unknown KIR2DL5, KIR2DS3 and KIR2DS5 genotypes was based on
previously reported haplotypes [26], and led to the genotypic
determination of all but two individuals for KIR2DL5 and all but one
individual for KIR2DS3. By contrast, substantial genotypic re-
construction was not possible for KIR2DL1, which was not in strong
LD with other KIRs. As KIR2DL1 was not expected to be informative
for the association study because of its very high phenotypic
frequency (.95%), this receptor was excluded from further analysis.
After these two reconstruction steps, study subjects had known
genotypes for eight KIR gene systems—KIR2DS2, KIR2DL2/2DL3,
Figure 1. Organisation of the human KIR cluster. The Killer-cell Immunoglobulin-like receptor (KIR) genes are organised in a head-to-tail fashion on
human chromosome region 19q13.4. Each gene has nine exons (illustrated for KIR3DL1) and is roughly 10–16 kb in length, with short and equally
homologous intergenic sequences of about 2 kb separating each pair of genes. The organisation of the exon-intron structure of the different KIR
genes is fairly consistent with the following basic arrangement: the signal sequence is encoded by the first two exons (in grey), each Ig domain (D0,
D1, D2) corresponds to a single exon (exons 3–5, respectively, in blue), the linker (in yellow) and transmembrane (in white) regions are each encoded
by a single exon (exons 6 and 7, respectively), and the cytoplasmic domain is encoded by two final exons (8 and 9, in red). Two systems have been
generated for naming KIR genes. The first follows the CD nomenclature system as CD158a, CD158b, etc., based on an approximate
centromerictelomeric order of the genes on chromosome 19 [58]. As the CD nomenclature is not used routinely since it does not reflect structure,
function, expression or localization, the Human Genome Organization (HUGO) nomenclature will be used throughout this report
(www.gene.ucl.ac.uk/nomenclature/genefamily/kir.html). The HUGO nomenclature system, accounts for KIR protein structure and consists of four
major subdivisions based on two features: the number of extracellular Ig domains (2D or 3D) and the length of the cytoplasmic tail (L: long or S:
short). This latter information determines their functions: inhibitory (L) or activating (S). The boxes in bold indicate the activating KIR genes, and the
dotted boxes correspond to the pseudogenes. The two boundary genes of the KIR cluster, KIR3DL3 and KIR3DL2, and the centrally situated KIR3DP1
pseudogene and KIR2DL4 are present in almost all individuals and are therefore considered to be framework (or anchor) genes (shown in white) [59].
KIR3DL3 and KIR3DP1 delimit the centromeric part of the KIR locus, whereas KIR2DL4 and KIR3DL2 delimit the telomeric part. A 14 kb stretch of unique
sequence separating KIR3DP1 from KIR2DL4 is the preferred site for reciprocal recombination, a mechanism resulting in the formation of new
haplotypes by the reassortment of centromeric and telomeric genes. Apart from these framework genes, KIR gene content is highly variable in terms
of both the number and type of genes present. Although initially considered to be separate genes, KIR2DL2 and KIR2DL3 segregate as alleles of the
same locus. Similarly, KIR3DS1 segregates as an allele of the inhibitory KIR3DL1. Overall, there are nine variable genes—KIR2DS2, KIR2DL2/2DL3,
KIR2DL1, KIR3DS1/3DL1, KIR2DL5, KIR2DS3, KIR2DS5, KIR2DS1, KIR2DS4—and one variable pseudogene (KIR2DP1). KIR2DL5 KIR2DS3 and KIR2DS5 may be
found in both parts of the locus. We decided to represent these genes in the telomeric part of the cluster in this figure. Two major KIR haplotype
groups, A and B, are classically described. The A haplotype is defined as containing the KIR3DL3, KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1, KIR2DS4 and
KIR3DL2 genes. KIR gene polymorphism adds further diversity to the KIR region, with multiple alleles known for each KIR locus. Allele identification
was performed for KIR2DL4, KIR2DS4 and KIR3DS1/3DL1 (indicated in red). This makes it possible to subdivide haplotype A further, according to the
presence of the two common forms of KIR2DS4—the wild type KIR2DS4wt (haplotype A1) or the deletion variant KIR2DS4del, identical to KIR2DS4wt
except for a 22 base-pair deletion causing a frame shift in translation (haplotype A2). B haplotypes are more variable and are characterised by the
presence of more than one activating KIR gene. Genes that can be present in both group A and group B KIR haplotypes are shown in brown, and
genes and/or alleles specific to group B KIR haplotypes are shown in green.
doi:10.1371/journal.pone.0000406.g001
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KIR3DS1/3DL1, KIR2DL5, KIR2DS3, KIR2DS5, KIR2DS1, and
KIR2DS4—which were used for the family-based association study
(Table 1). All these KIR gene systems were diallelic (+,2), except
KIR2DS4, which was triallelic (+wt, +del, and2). Allelic frequen-
cies ranged from 0.15 for KIR2DS3+ to 0.77 for KIR2DS4+ (0.58
for KIR2DS4del and 0.19 for KIR2DS4wt). The eight KIR gene
systems were in Hardy-Weinberg equilibrium. The frequencies of
the three main KIR haplotypes, A1, A2 and B, estimated from
these family data were 0.46, 0.12, and 0.42, respectively, consistent
with the haplotype A and B frequencies reported in other
populations of European origin [32,33].
Association study of HL with KIR genotypes
The results of the family-based study of association between HL and
the eight KIR gene systems are presented in Table 2, assuming
a dominant mode of inheritance, which gave the best fit in con-
ditional logistic regression analysis. Alleles KIR3DS1+, KIR2DL5+,
KIR2DS5+and KIR2DS1+were significantly associated (p,0.05) with
a protective effect against HL whereas allele KIR2DS4del was
associated with an increase in the risk of HL. The strongest effects
were observed for alleles KIR3DS1+(p,0.006), and KIR2DS1+
(p,0.01). Under a model of dominant inheritance, the odds ratio
(OR) for developing HL in subjects homozygous KIR3DS1(+,+) or
heterozygous KIR3DS1(+,2) with respect to subjects homozygous
KIR3DS1(2,2) was 0.44 [95% confidence interval: 0.23–0.85].
Similarly, the OR for KIR2DS1(+,+) or KIR2DS1(+,2) subjects with
respect to KIR2DS1(2,2) subjects was 0.42 [0.21–0.85].
As the five KIR genes significantly associated with HL were in
strong LD (Figure 4), the next step was to carry out both multi-
variate and haplotype analyses. Multivariate conditional logistic
regression demonstrated that the association between HL and the
KIR region was supported by a single signal. Once one of the five
associated KIR genes was entered in the regression model,
particularly for the most significant system, KIR3DS1/3DL1, the
other four genes ceased to have a significant effect. Haplotype
analysis provided further detail. It showed that, due to LD, the five
associated KIR genes were organised into only five common
haplotypes (frequency.0.02), accounting for 96% of the haplo-
types observed in our population (Table 3). The two haplotypes
significantly associated with a protective effect against HL (H2 and
H5 in Table 3) contained the same alleles for KIR3DS1 (+),
KIR2DL5 (+), KIR2DS1 (+), and KIR2DS4 (2), but different alleles
for KIR2DS5 (+ and 2, respectively). We also noted that the two
protective haplotypes H2 and H5 did not carry KIR2DS4, whereas
the risk-associated haplotype (H1) carried the deleted form,
resulting in the production of a truncated protein predicted to
have no functional effect [34,35]. These observations made
KIR2DS5 and KIR2DS4 unlikely candidates for the observed
effect. Finally, haplotypes H3 and H4 which carried different
KIR2DL5 alleles, seemed to have opposite effects, although this
difference was not significant. Thus, these results suggest that the
protective effect against HL is mediated by the presence of
KIR3DS1 or KIR2DS1 or both genes.
We then investigated whether the association between
KIR3DS1, KIR2DS1 and HL was influenced by the HLA class I
status of the patients, according to their known ligand specificity.
For KIR3DS1, we considered the HLA–B genotype, as determined
by the Bw4I80 allele and, for KIR2DS1, we considered the HLA–C
genotype, as determined by the C2 allele. No significant
heterogeneity (p.0.79) was found in the association between
KIR3DS1 and HL, according to the presence or absence of the
Bw4I80 allele (Table 4). For KIR2DS1, the protective effect seemed
to increase with the number of HLAC2 alleles, although the
heterogeneity test was not significant (p = 0.35) (Table 4). The OR
decreased from 0.52 [0.17–1.65] for C1/C1 homozygotes to 0.37
[0.15–0.90] for subjects with at least one C2 allele. Interestingly,
when we considered the presence of both ligands (i.e. patients with
at least one Bw4I80 allele and one C2 allele), the protective effect
of KIR2DS1 and KIR3DS1 tends to be stronger with an OR of 0.21
[0.04–1.07] for both KIR alleles. However, the number of
informative families in this latter analysis was small (seven
families), precluding to draw definitive conclusion from this result.
Finally, we investigated the role of some of the characteristics of
EBV-infected patients, focusing on the EBV status of the tumour
(positive/negative) or EBV load in peripheral blood mononuclear
cells (detectable/undetectable). No significant heterogeneity in the
association between HL and KIR3DS1 or KIR2DS1 was found for
any of these characteristics (Table 4). However, the protective
effect seemed to be stronger in patients with EBV-positive tumours
or detectable viral load. This effect was clearest for KIR3DS1, with
an OR of 0.27 [0.08–0.87] for patients with detectable viral load
(40% of patients) versus 0.61 [0.27–1.37] for those with no
detectable viral load (60%).
We tried to replicate these results by comparing KIR phenotype
frequencies in the independent sample from the ENGELA study
consisting of 68 HL patients and 60 controls. In this sample, no
significant association was observed between any KIR phenotype
and HL. Further analyses stratified for age (e.g. restricted to the
15–35 age class), HLA class I genotype, and the EBV status of
tumour tissues identified no HL subgroup associated with
KIR3DS1 or KIR2DS1. In this sample, the frequencies of positive
phenotypes for KIR3DS1 and KIR2DS1 among HL cases were
43% (29/68) and 41% (28/68), respectively. These frequencies
were higher than for the 84 index HL cases of the familial study
(33% for both KIR phenotypes), although these differences were
not significant (p = 0.27 and 0.24 respectively).
DISCUSSION
We report here the first family-based association study to show an
association between a disease and genes of the KIR cluster.
Familial studies have been conducted to determine the structure of
the KIR region [26,36], but the previously reported associations
between the presence/absence of KIRs and various disease
phenotypes were identified in case/control studies [25]. Family-
based association studies have important advantages over case/
control studies in that they can make use of full genotypic
information at KIR loci (number of gene copies) and make it
possible to avoid the possible confounding of gene-phenotype
associations due to inappropriately chosen controls or population
Figure 2. Phenotypic distribution of KIRs in Hodgkin’s lymphoma
cases. The proportion (percentages) of present KIR genes, as de-
termined by KIR gene content analysis are presented for the index HL
cases (n = 90). Eleven KIR genes are presented in the figure. Two pairs of
KIR genes are allelic: KIR3DL1/3DS1, and KIR2DL2/2DL3.
doi:10.1371/journal.pone.0000406.g002
KIRs and Hodgkin’s Lymphoma
PLoS ONE | www.plosone.org 4 May 2007 | Issue 5 | e406
Figure 3. Genotypic reconstruction. KIR gene content analysis provides only binary phenotyping results for each KIR (absent or present), rather than
complete genotypic information. Thus, for genotype analysis (i.e. the number of copies of each KIR gene), genotypic reconstruction in two successive
steps was required. The first step combined the results of KIR gene content analysis, knowledge of allelic forms of KIRs, the additional allele typing
carried out for three KIR genes, and the analysis of intra-familial segregation. KIR gene content made it possible to determine genotype
unambiguously only in individuals with a negative phenotypic result. For example, an individual with a negative KIR2DS2 phenotype has no copy of
the gene, and its genotype can be deduced and denoted KIR2DS2(2,2). Conversely, an individual with a positive phenotype for KIR2DS2 may have
either one copy of the gene, denoted KIR2DS2(+,2), or two copies of the gene, denoted KIR2DS2(+,+). Two of the nine variable KIR genes have known
allelic forms: KIR2DL2/2DL3 and KIR3DS1/3DL1. We defined as (+,+) the KIR3DS1/3DL1 genotype of subjects homozygous for the presence of KIR3DS1
(phenotype KIR3DS1+, KIR3DL12) and as (2,2) the genotype of subjects homozygous for the absence of KIR3DS1 (phenotype KIR3DS12, KIR3DL1+).
An individual with the KIR3DS1+, KIR3DL1+ phenotype has one copy of each gene and is therefore heterozygous at the locus, with genotype KIR3DS1/
3DL1(+,2). The genotypes of KIR2DL2/2DL3 followed the same principle. Additional KIR allele typing was especially useful for the analysis of familial
gene segregation. In particular, for KIR2DS4, it made it possible to distinguish between the two common forms, 2DS4wt and 2DS4del (Figure 1). The
second step of the reconstruction was based on the KIR haplotype determination of individuals in each family. We first estimated the pairwise linkage
disequilibrium (LD) pattern between KIR genes in our families, using the genotypic information obtained from the first step of reconstruction (see
statistical analysis). Perfect and complete LD between pairs of KIRs made it possible to infer certain genotypes. For the few remaining unsolved KIR
genotypes, haplotypic reconstruction was based on previously described haplotypes [26,33].
doi:10.1371/journal.pone.0000406.g003
Table 1. Summary of the genotypic reconstruction results for the nine variable KIR genes in 322 subjects. The procedure of
reconstruction is detailed in figure 3.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KIR 2DS2 2DL2/2DL3 2DL1 3DS1/3DL1 2DL5 2DS3 2DS5 2DS1 2DS4
Patients with known genotype:
-after the 1st step N (%) 216 (67) 322 (100) 27 (8) 322 (100) 231 (72) 285 (89) 280 (87) 268 (83) 193 (60)
-after the 2nd step N (%) 322 (100) 322 (100) 27 (8) 322 (100) 320 (99) 321 (100) 322 (100) 322 (100) 322 (100)
Allele frequencya 0.33 0.33/0.67 -b 0.25/0.75 0.29 0.15 0.19 0.23 0.77
aestimated from all the reconstructed genotypes after the 2nd step.
bexcluded after the second step of reconstruction.
doi:10.1371/journal.pone.0000406.t001..
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admixture. A first phase of genotypic reconstruction is required,
based principally on a combination of information from the familial
data. Published data were required for the full determination of only
a minority of genotypes (for KIR2DL5, KIR2DS3 and KIR2DS5), and
KIR2DL1 was the only locus that could not be reconstructed, due to
its high frequency. We propose a method of KIR genotypic
reconstruction in familial samples that could be applied to other
family-based studies, as already demonstrated for a sample of African
origin (S.R. et al., unpublished data).
Host genetic factors are known to be important in HL
pathogenesis [4–7,11], and many association studies have sug-
gested a possible association between HL and HLA genes [8–10].
Given the strong link between EBV and HL and the role of HLA
in the presentation of viral antigens, EBV specificities in the role of
HLA genes in HL have recently been investigated. An association
was found between EBV-positive HL and markers located in the
HLA class I region, whereas EBV-negative HL was found to be
associated with markers of the HLA class III region [10].
However, no consensus has yet emerged on the role of any
specific HLA molecule [8–10]. KIRs were considered as candidate
genes for HL predisposition in this study since they are alternative
receptors for HLA class I molecules.
Our family-based analysis provides the first evidence for an
association between HL and certain KIR alleles in strong linkage
disequilibrium. Refined haplotype analysis results were consistent
with a dominant protective effect of KIR3DS1 and/or KIR2DS1
against HL. The validity of our familial analysis is also streng-
thened by the observation of random transmission of the KIR
alleles considered in the 100 unaffected children of our sample (i.e.
the healthy siblings of HL patients). We tried to replicate this
association, using a case/control sample collected in the context of
a French survey on adult lymphoma and including 68 HL patients.
No significant association between HL and the presence/absence
of any KIRs was found. The HL patients did not differ between the
two samples in terms of ethnic origin and clinical features. EBV
viral load in peripheral blood mononuclear cells was not
determined in the case/control study, whereas we found that the
protective effect of KIR3DS1 and/or KIR2DS1 in familial sample
Figure 4. Pairwise linkage disequilibrium between KIR genes in the family sample. This analysis was based on the genotypes reconstructed after
the first step, without using any information about LD pattern between KIR genes. Each square represents the magnitude of pairwise LD between KIR
genes, as measured by D’ (panel A) or r2 (panel B). Red squares represent a |D’| or r2 value of 1.0, corresponding to complete and perfect LD,
respectively. Orange, yellow, and white squares indicate |D’| or R2 values of [0.75-1[, [0.5-0.75[, and,0.5, respectively.
doi:10.1371/journal.pone.0000406.g004
Table 2. Results of the family-based association study between KIR genes and Hodgkin’s lymphoma using a dominant model
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KIR frequency present allele N informative familiesa p-valueb Odds Ratio [95% CI]c Effect
2DS2 0.33 37 0.89 1.13 [0.55–2.34] _
2DL2/2DL3d 0.33/0.67 37 0.89 1.13 [0.55–2.34] _
3DS1/3DL1d 0.25/0.75 41 0.006 0.44 [0.23–0.85] protective
2DL5 0.29 41 0.02 0.56 [0.30–1.04] protective
2DS3 0.15 37 0.11 0.65 [0.34–1.25] _
2DS5 0.19 31 0.05 0.49 [0.23–1.04] protective
2DS1 0.23 37 0.01 0.42 [0.21–0.85] protective
2DS4dele 0.58 30 0.03 2.22 [0.94–5.27] at risk
2DS4wtf 0.19 30 0.67 1.02 [0.50–2.1] _
ainformative families are those with at least one heterozygous (+,2) parent for the corresponding KIR gene.
bcomputed using the FBAT software.
ccomputed by conditional logistic regression.
dassociation results for allelic forms of the same KIR locus are provided for the first variant of the pair.
edeleted form
fwild type
doi:10.1371/journal.pone.0000406.t002..
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tended to be stronger in patients with detectable viral load. We
also restricted the analysis to the 34 patients belonging to the same
age class (15–35 years) as our familial patients, corresponding to
the first peak of HL incidence in developed countries, but no
significant association was observed in this small sample. In any
case, a larger sample is certainly required for a more powerful
replication study.
Due to strong linkage disequilibrium, it was almost impossible to
distinguish between the effects of KIR2DS1 and KIR3DS1. The
observed trend for the protective effect of KIR2DS1 to increase in
the presence of its putative ligand, HLA-C2, may be more
consistent with a role for this receptor although the effectives of
each strata are small. We cannot exclude the possibility that both
these KIRs are responsible for the observed protective effect, as
different cognate KIR-HLA class I pairs may have the same
biological effects, since, for example, all activating KIR-S share the
same KARAP/DAP12-dependent signalling pathways [37]. This
hypothesis is supported by the trend toward a stronger protective
effect in presence of at least one allele of each HLA class I ligands
of KIR3DS1 and KIR2DS1, and the even greater trend in presence
of both ligands. Our results are consistent with those of a study
showing the protective effect of KIR3DS1 against HCV-related
hepatocarcinoma [29], and with the general idea that activating
KIRs are beneficial for the response to infectious diseases and
tumours. However, immune activation may not be beneficial at all
stages of these disorders and could, for example, increase the risk
of other tumours associated with local inflammation [25]. This
may account for two other reports of activating KIRs being
associated with an increase in the risk of virus-related localised
cancers, such as NPC [31] and cervical cancer [30].
We observed an interesting trend towards a stronger protective
effect of KIR2DS1 and/or KIR3DS1 in the presence of EBV,
Table 4. Effect of KIR3DS1 and KIR2DS1 stratified on HL patients characteristics
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KIR3DS1 KIR2DS1
HL cases
N informative
families Odds-Ratio [95% CI]a pb
N informative
families Odds-Ratio [95% CI]a pb
All 41 0.44 [0.23–0.85] 0.006 37 0.42 [0.21–0.85] 0.01
HLA-B
No Bw4I80 allele 30 0.46 [0.21–1.01] 0.01 - - -
At least one Bw4I80c 11 0.38 [0.11–1.31] 0.24 - - -
HLA-C
C1/C1 - - - 13 0.52 [0.17–1.65] 0.23
At least one C2 - - - 24 0.37 [0.15–0.90] 0.02
HLA-B and -C combined
C1/C1 or no Bw4I80 34 0.51 [0.25–1.06] 0.04 30 0.52 [0.23–1.10] 0.10
At least one Bw4I80 and one C2 7 0.21 [0.04–1.07] 0.03 7 0.21 [0.04–1.07] 0.03
EBV in situd
EBV+ 8 0.24 [0.05–1.24] 0.09 7 0.28 [0.05–1.51] 0.14
EBV2 22 0.37 [0.14–0.97] 0.02 19 0.37 [0.13–1.04] 0.04
EBV load in PBMCse,f
detectable 16 0.27 [0.08–0.87] 0.02 15 0.28 [0.09–0.92] 0.03
undetectable 24 0.61 [0.27–1.37] 0.15 22 0.54 [0.22–1.23] 0.17
acomputed by conditional logistic regression
bcomputed by the FBAT software under a dominant model
cat least one present allele. Only two HL patients are Bw4I80 homozygotes.
dmissing in 11 cases
emissing in 1 case
fPBMCs corresponds to peripheral blood mononuclear cells
doi:10.1371/journal.pone.0000406.t004..
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Table 3. Association study based on haplotypes constructed from five KIR genes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No 3DS1 2DL5 2DS5 2DS1 2DS4 Estimated frequency N fam p-value Effect
H1 - - - - dela 0.55 31 0.04 at risk
H2 + + + + - 0.15 29 0.03 protective
H3 - - - - wtb 0.15 30 0.54 _
H4 - + - - dela 0.06 16 0.56 _
H5 + + - + - 0.05 11 0.03 protective
Analysis performed with the FBAT software using a dominant model
adeleted form
bwild type
doi:10.1371/journal.pone.0000406.t003..
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detected in either HL tumour cells or in peripheral mononuclear
blood cells. This suggests that the protective role of activating
KIRs may be more pronounced in HL cases associated with EBV.
NK cells were recently shown to limit lytic EBV infection through
the down-regulation of MHC class I molecules that bind to
inhibitory KIRs, and up-regulation of activating ligands such as
ULBP-1 and CD112 [38]. An indirect control of virus replication
by cytokines produced by NK cells may also be involved in this
protective effect, as shown for mouse cytomegalovirus [39]. We
favor another model for the potential role of NK cells in the
control of HL via activating KIRs. The malignant Hodgkin/Reed-
Sternberg (HRS) cells of EBV-associated HL display high-level
expression of MHC class I molecules [12,13,41]. The up-
regulation of HLA class I-peptide complexes in HRS cells would
then trigger NK cell effector functions via activating KIRs, leading
to the participation of NK cells in the control of HL. This
hypothesis is consistent with previous biological findings as
KIR2DS1 has been shown to recognize peptide-HLA class I
complexes that are up-regulated on EBV human infected B cells
[27]. Similarly, the control of mouse cytomegalovirus infection in
certain strains of mice involves the recognition of peptide-MHC
class I complexes through the activation of Ly49 receptors [40].
To further confirm our hypothesis, it will be of particular interest
to follow the activation of NK and T cell subsets according to the
presence of KIR2DS1 and/or KIR3DS1 when the detection of these
receptors will be possible. In any case, the recognition of HL cells
by KIRs warrants further investigation, and we are currently
carrying out an immunohistological study, comparing the presence
of NK cells in EBV-positive and EBV-negative HL specimens.
METHODS
Study population
HL index cases were recruited from three haematology units in the
Paris area. Patients were included at diagnosis (n = 21) or whilst in
complete remission, at least one year after diagnosis (n = 69).
Inclusion criteria were age between 15 and 35 years and negative
serological tests for HIV at diagnosis. Tumour biopsies were
reviewed by expert haematological pathologists (JB, DC, MR).
Intratumoral EBV expression was assessed by mRNA in situ
hybridisation for Epstein-Barr virus-encoded small non polyade-
nylated RNA (EBER1) sequences or by indirect immunofluores-
cence staining for latent membrane protein 1 (LMP1). First-degree
relatives (parents and siblings) of the patients were asked to
participate in the study. All participating subjects were interviewed
to determine their medical history, and all gave a blood sample for
DNA extraction and EBV measurements. EBV viral load was
measured in peripheral blood mononuclear cells, as previously
described [42]. All recruited families (n = 90) included the index
HL case and at least two other individuals (either both parents or
one parent and one unaffected sibling). Five of the 90 families were
multiplex (three families with two affected siblings, and two
families with an affected parent and an affected child).
In addition to this family sample, we also studied a case-control
sample recruited in the framework of the ENGELA (Environnement
et Ge´ne´tique des Lymphomes de l’Adulte) study on adult lymphoma. This
study was conducted in six French cities (Brest, Bordeaux, Caen,
Lille, Nantes and Toulouse), and included newly diagnosed HIV-
negative HL cases confirmed by histology. Controls and cases
were matched for centre, sex, age (63 years) and ethnic origin,
with the controls hospitalised or consulting at the same hospitals as
the cases, but for reasons other than cancer, occupational diseases
or injuries, and tobacco-or alcohol-related diseases. DNA samples
were available for 68 Caucasian cases (52 with nodular sclerosis,
11 with mixed cellularity, 5 with HL of another or an unspecified
type), including 40 men and 28 women, and 60 Caucasian controls
(36 men and 24 women), mostly from orthopaedic departments.
The subjects included were aged 18 to 71 years, and 32 cases and
23 controls were less than 35 years old. The EBV status of tumour
tissue was available for 46 cases, 13 (28%) of which were positive.
Both studies were approved by the French Consultative
Committee for Protecting Persons in Biomedical Research
(CCPPRB) of Paris Necker and Kremlin-Biceˆtre, respectively.
Human experimentation guidelines were followed in the conduct
of the research. Informed consent was obtained from adults or
from parents of minors.
Molecular methods
KIR gene content KIR gene content was determined with an
updated version of the previously reported PCR-SSOP technique
[43], which consists in oligonucleotide primers and probes selected
from the first KIR gene typing system, as described in [44]. Briefly,
we used two separate locus-specific PCR to amplify the D1, D2
and transmembrane/cytoplasmic tail regions. The D1 and D2
regions were amplified together, with primers flanking exons 4 and
5; 59AGAGAXXGTCATCCTGCA(A/G)TGTTGGTC 39 (exon
4, nucleotides 56-82) and 59CTCACCTXTGAC(G/A)GAAAC-
AAGCAGTGG 39 (intron 5-273 exon 5). The transmembrane/
cytoplasmic tail region was amplified as previously described. PCR
products were blotted onto nylon membranes and hybridised with
19 digoxigenin-labelled sequence-specific oligonucleotide probes,
using hybridisation and chemiluminescence procedures, as
previously described. Internal control samples, identified with
a unique probe pattern, were also included in each experiment.
Additional KIR allele typing KIR2DL4, KIR2DS4 and
KIR3DS1/3DL1 alleles were identified using previously described
SSOP techniques, based on a gene-specific PCR product
[36,45,46]. KIR2DL4 allele typing consists involves the PCR
amplification of a 1440 bp region of KIR2DL4 exons 3/5 (D0/D2
domains), followed by hybridisation, using 16 digoxigenin-labelled
probes for allele discrimination. The KIR2DS4 allele typing system
is based on the specific amplification of the 199/221bp region of
KIR2DS4 exon 5 (D2 domain) and 11 probes were used for allele
identification. Finally, the KIR3DS1/3DL1 allele typing strategy
uses three separate specific amplifications of the extracellular D0
(exons2/3), D1 and D2 domains (exons 4/5) and a section of the
cytoplasmic tail (exons 8/9), respectively. The third amplification
concerned a single region of KIR3DS1 only, and was required for
discrimination between certain KIR3DS1 alleles. The amplified
DNA was subjected to SSOP typing, using a total of 28 oligo-
nucleotide probes, as previously reported. In each system, a set of
nine internal control samples with a unique pattern of probe
reactivity was included among the samples investigated. Com-
putational analysis was carried out on the data obtained with the
various probes, to identify the alleles of each gene present.
HLA class I KIR ligand typing The study was focused on
the identification of HLA-Bw4 and HLA-C1/C2 KIR ligands,
that were typed using updated methods, as described in [47].
Briefly, we used four probes (BL20, BL21, BL22, BL23) to define
HLA-Bw4, with the same PCR conditions as the previously report
typing system for HLA–B [48]. These probes are able to
distinguish threonine or isoleucine present at position 80 of the
HLA-Bw4 molecules. Similarly, HLA-C1 and C2 groups were
defined using only two probes from the full HLA–C allele typing
system [49], which differentiated nucleotides at positions 77 and
80. These probes were C293 for C1 group and C291 for C2
group.
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Statistical analysis
Hardy-Weinberg equilibrium was tested after genotypic recon-
struction for each KIR gene, using all the parents of the families.
Measures of pairwise linkage disequilibrium (LD) between KIR
genes, such as D’ and r2 [50], were estimated using Haploview
(http://www.broad.mit.edu/personl/jcbarret/haplo/). |D’| and
r2 vary between 0 and 1. Complete LD in a pair, defined as
|D’| = 1, is obtained when one of the four possible haplotypes is
not observed. Perfect LD between two KIR genes, defined as
r2 = 1, is reached when two of the four possible haplotypes are not
observed, i.e |D’| = 1 and the frequencies of the (+,2) alleles of
the two KIR genes are equal.
The main association study was conducted on the family
sample, using specific methods developed in this context. Family-
based association studies avoid the possible confounding of gene-
phenotype associations due to inappropriately chosen controls that
can occur in case/control studies. The general principle of these
studies is to search for a distortion of the transmission of alleles
from parents to affected offspring, by means of the ‘‘transmission
disequilibrium test’’ (TDT) [51]. Families with one missing parent
(30/84 in our sample) can be analysed either by reconstructing
parental genotypes from children (RC-TDT) [52], or by using
unaffected siblings as controls (Sib-TDT) [53]. The family-based
association study was carried out mainly according to the method
implemented in the FBAT program [54], which combines these
three different methods (TDT, RC-TDT, and Sib-TDT). This
method also allows the use of an empirical variance-covariance
estimator for the statistic, which is consistent when sibling marker
genotypes are correlated (e.g. when the analysis includes multiple
affected sibs) [55]. Finally, alleles for which evidence of association
was obtained were also analysed by conditional logistic regression,
as previously described [56]. This analysis generated odds-ratio
(OR) estimates and made it possible to compare different models
of dominance (recessive, dominant or additive). It also made it
possible to test for heterogeneity of the sample according to
a qualitative criterion (e.g. HLA class I genotypes) by performing
the analysis on the whole sample, and separately on subsamples, as
described elsewhere [57]. For the association study conducted on
the case/control sample, KIR phenotype distributions were
compared between HL patients and controls, using classical chi-
squared tests. Conditional logistic regression analyses (proc
PHREG) and chi-squared tests (proc FREQ) were carried out
with SAS software (version 8.2, SAS Institute, Cary, NC).
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